Related Experiment Video
Updated: Aug 10, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced
F Bendjelloul1, P Malý, V Mandys
1Division of Immunology and Gnotobiology, Institute of Microbiology, Charles University, Institute of Experimental Medicine, ASCR, Prague, Czech Republic.
Insights
Mice lacking intercellular adhesion molecule-1 (ICAM-1) showed reduced mortality and intestinal inflammation in experimental colitis models. This highlights ICAM-1
Area of Science:
- Immunology
- Gastroenterology
- Molecular Biology
Background:
- Intercellular Adhesion Molecule-1 (ICAM-1) is upregulated on activated vascular endothelium during inflammation.
- ICAM-1 acts as a ligand for LFA-1 and Mac-1, mediating cell adhesion.
- Its precise role in intestinal inflammation requires further elucidation.
Purpose of the Study:
- To investigate the role of ICAM-1 in the development of acute and chronic experimental intestinal inflammation.
- To assess the impact of ICAM-1 deficiency on colitis severity and mortality in a mouse model.
Main Methods:
- Experimental colitis was induced in ICAM-1-deficient and control C57Bl/6J mice using dextran sodium sulphate (DSS).
- Mortality rates, clinical signs (diarrhea, rectal bleeding), and histological changes in the large bowel were evaluated.
- Serum levels of anti-epithelial IgA autoantibodies were measured in chronic colitis models.
Main Results:
- ICAM-1-deficient mice exhibited significantly lower mortality rates (5%) compared to controls (35%) in acute colitis.
- Fewer mucosal defects and milder inflammatory infiltrates were observed in ICAM-1-deficient mice.
- Chronic colitis showed less severe inflammatory changes in ICAM-1-deficient mice, with no increase in anti-epithelial IgA autoantibodies.
Conclusions:
- ICAM-1 plays a significant role in the pathogenesis of experimentally induced intestinal inflammation.
- Targeting ICAM-1 may represent a therapeutic strategy for inflammatory bowel diseases.
- ICAM-1 deficiency ameliorates both acute and chronic DSS-induced colitis in mice.
Abstract:
ICAM-1 (CD54), the ligand for LFA-1 and Mac-1, is up-regulated during inflammatory reaction on the activated vascular endothelium. To determine its role in intestinal inflammation, we induced acute experimental colitis in mice with a deleted ICAM-1 gene, by feeding them with 3% dextran sodium sulphate (DSS) in drinking water for 7 days. Chronic colitis was elicited by DSS similarly, followed by 2 weeks with water. In the acute phase of inflammation, ICAM-1-deficient mice exhibited a significantly lower mortality rate (5%) than control C57Bl/6J mice (35%). Control animals, but not the ICAM-1-deficient mice, exhibited diarrhoea and rectal bleeding. Histological examination of large-bowel samples evaluated the intensity of inflammatory changes, and type and extent of mucosal lesions. In the acute phase, 33.3% of samples from ICAM-1-deficient mice exhibited mucosal defects (flat and fissural ulcers), predominantly mild to moderate inflammatory infiltrate within the lamina propria mucosae and lower grades of mucosal lesions. Much stronger inflammatory changes were present in control animals, flat ulcers (sometimes multiple) and fissural ulcers being observed in 62.5% of samples. Mucosal inflammatory infiltrate was moderate to severe, typically with higher grades of mucosal lesions. In chronic colitis, smaller inflammatory changes were found in the large bowel. The two mouse strains differed, the chronic colitis being accompanied by an increased serum level of anti-epithelial IgA autoantibodies in C57Bl/6 control mice but not in ICAM-1-deficient mice. These findings provide direct evidence of the participation of ICAM-1 molecule in the development of experimentally induced intestinal inflammation.
More Related Videos
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025